Higher Cytogenetic Response Rates

With Gleevec®*

Major Cytogenetic Response† Complete Cytogenetic Response‡

0

20

40

60

80

100

Gleevec IFN-α +

ara-C

% of Patients

0

20

40

60

80

100

Gleevec IFN-α +

ara-C

% of Patients

76%§

12%

54%§

3%

§P<0.001. Confirmed responses shown.

Unconfirmed MCR—Gleevec: 83%; IFN-α + ara-C: 20%.

Unconfirmed CCR—Gleevec: 68%; IFN-α + ara-C: 7%.

*IRIS Study; n=553 in each arm.

†≤35% Ph+ cells.

‡0% Ph+ cells.

For important safety information, please see

slide 3 or full Prescribing Information.

[Slide 15]

Higher Cytogenetic Response Rates With Gleevec®1,2

• The data were analyzed using Fischer’s Exact Test.

• A statistically significantly higher percentage of patients achieved a major cytogenetic response (≤35% Ph+ cells) with Gleevec (76% confirmed, 83% unconfirmed) versus IFN-α

+ ara-C (12% confirmed, 20% unconfirmed); P<0.001.

• A statistically significantly higher percentage of patients achieved a complete cytogenetic

response (0% Ph+ cells) with Gleevec (54% confirmed, 68% unconfirmed) versus IFN-α + ara-C

(3% confirmed, 7% unconfirmed); P<0.001.

• Confirmed responses were observed on 2 occasions ≥4 weeks apart; unconfirmed responses

were observed on 1 occasion.

References

1. Gleevec® (imatinib mesylate) Prescribing Information. East Hanover, NJ: Novartis

Pharmaceuticals Corporation; 2003.

2. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.